Weishi Pharmaceuticals

Weishi Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for oncology and immunology. The company focuses on modulating the immune system by targeting key regulators in the tumor microenvironment to overcome immune suppression. Its lead program, WS-015, is a potent and selective inhibitor of Hematopoietic progenitor kinase 1 (HPK1), currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Weishi leverages its deep expertise in medicinal chemistry and tumor biology to advance a pipeline of novel drug candidates. The company aims to address significant unmet medical needs by providing next-generation immunotherapies for cancer patients worldwide. Weishi is backed by prominent venture capital firms and led by an experienced management team with a track record in global drug development.